[{"Assets_0_Q1_USD":249296000.0,"EarningsPerShareBasic_1_Q1_USD":0.18,"EarningsPerShareDiluted_1_Q1_USD":0.17,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":4921000.0,"NetIncomeLoss_1_Q1_USD":2616000.0,"StockholdersEquity_0_Q1_USD":178177000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":15478335.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":14819530.0,"Ticker":"EGRX","CIK":"827871","name":"EAGLE PHARMACEUTICALS, INC.","OfficialName":"Eagle Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20180331","fy":"2018.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"635235963.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180510"}]